Low-dose glucocorticoid use during the maintenance phase was associated with a significantly increased risk for new damage accumulation or hospitalization.
TOPICAL: Randomized phase III trial of erlotinib compared with placebo in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) and unsuitable for first-line chemotherapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results